BioSpace News Archive

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021, respectively Four abstracts featuring Oral Paclitaxel accepted for presentation at San Antonio Breast Cancer Virtual Symposium Product sales in Q3 2020 were $24.8 million, up 29% y/y -- raising full year 2020 guidance to low 20% growth

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update. “We maintain our focus on executing strategic partnerships and collaborations. As such, we were delighted in recent weeks to announce a new research collabor

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing third quarter highlights at 4:30 p.m. ET on Monday, November 9th, 2020 .

Net sales of $111.0 million, an increase of 52% sequentially and within 2% of our 2019 performance US Spinal Implants third quarter net sales increased 19% over the prior year Motion Preservation sales in the U.S. of $5.2 million, an increase of 44% sequentially and over 400% over prior year Entered into an investment and co-development partnership with Neo Medical SA

- Three clinical trials of novel Bicycles ® initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149 - Cash was $149.8 million at September 30, 2020, which includes net proceeds received during Q3 from completion of $50.0 million at-the-market (ATM) offering program and initial $15.0 million drawn from debt financing

Worldwide revenue of $88.5 million for the third quarter 2020, representing an increase of 3.2% from the prior year period Net loss of $6.4 million for the third quarter 2020, compared to net income of $4.9 million in the prior year period

Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1.940 billion Strong momentum behind commercial launches of both Monjuvi ® (tafasitamab-cxix) and Pemazyre ® (pemigatinib) in the U.S.

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 a.m. ET to discuss third quarter 2020 financial results and provide a general business update.

AVEO Oncology and EUSA Pharma announced that previously reported results from the Phase 1b/2 TiNivo study of oral tivozanib, AVEO’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor drug candidate, in combination with intravenous nivolumab, an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma, were published in Annals of Oncology.

Bristol Myers Squibb announced that data from 26 company-sponsored and collaborative studies, which demonstrate the depth and breadth of the company’s immunology pipeline and portfolio and commitment to the rheumatology community, will be presented at the American College of Rheumatology Convergence 2020, taking place virtually November 5-9, 2020.